Literature DB >> 27386899

First-line treatment in NSCLC harboring EGFR common mutations: EGFR TKI in monotherapy or in combination with anti-VEGF?

Antonio Passaro1, Gianluca Spitaleri1, Filippo de Marinis1.   

Abstract

Entities:  

Keywords:  EGFR; NSCLC; TKI; angiogenesis; bevacizumab; erlotinib; tyrosine kinase inhibitor

Mesh：

Substances：

Year:  2016        PMID： 27386899     DOI： 10.1080/14737140.2016.1210007

Source DB:  PubMed          Journal:  Expert Rev Anticancer Ther        ISSN： 1473-7140            Impact factor:   4.512


× No keyword cloud information.
  1 in total

1.  Metastasis-associated protein 2 promotes the metastasis of non-small cell lung carcinoma by regulating the ERK/AKT and VEGF signaling pathways.

Authors:  Bin Zhang; Feng Tao; Hao Zhang
Journal:  Mol Med Rep       Date:  2018-02-01       Impact factor: 2.952
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.